Perinatal EvidenceCompass
Prepopulated workbenchMED-250

Psychiatric adjuncts — movement disorders/EPS

Valbenazine

Treatment of extrapyramidal symptoms or tardive dyskinesia; indication varies

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Valbenazine
Entity type
single-ingredient drug
Active component(s)
Valbenazine
Formulation / route / interval
Oral; formulation varies
Attachment entry
Valbenazine
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

2 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-032Provisional public source

Human pregnancy and infant-outcome evidence for valbenazine, deutetrabenazine and tetrabenazine is essentially absent; nonpregnant TD efficacy does not establish fetal or lactation safety.

Public-source certainty descriptor
Very low reproductive certainty
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy and lactation
Comparator
VMAT2 inhibitor exposure versus unexposed
Effect or numbers carried forward

No adequate human pregnancy cohorts

Limitations

Labels rely heavily on animal data; untreated severe TD can itself impair nutrition and function

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-033Provisional public source

Valbenazine labeling advises no breastfeeding during treatment and for five days after the final dose.

Public-source certainty descriptor
High label certainty; no direct infant-outcome evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Lactation
Comparator
Breastfeeding versus temporary interruption/alternative treatment
Effect or numbers carried forward

Five-day interval after final dose

Limitations

Label precaution is based on absence/animal milk data rather than observed human infant harm

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending